Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05708573 · ClinicalTrials.gov registry record · Phase 1
Potential Drug Interaction Between ALXN2040 and Rosuvastatin
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT05708573 is a Phase 1 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT05708573, a Phase 1 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will assess the potential drug-drug interaction (DDI) between ALXN2040 and rosuvastatin.
Interventions
- DRUG Rosuvastatin
- DRUG ALXN2040
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2023-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05708573
The ClinicalTrials.gov registry entry for NCT05708573 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rosuvastatin is the first listed.
NCT05708573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05708573 about?
NCT05708573 is a clinical study titled "Potential Drug Interaction Between ALXN2040 and Rosuvastatin". This study will assess the potential drug-drug interaction (DDI) between ALXN2040 and rosuvastatin.
What is the current status of trial NCT05708573?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-02-01. Estimated completion is 2023-04-05.
What interventions are being tested in trial NCT05708573?
The interventions under investigation include: Rosuvastatin (DRUG), ALXN2040 (DRUG).
Who is sponsoring clinical trial NCT05708573?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.